There have been many changes in nuclear medicine and molecular imaging field as several radiopharmaceuticals have recently been approved and many others on the horizon. Ensuring the compliance with the increasingly aggressive national, federal, and state regulatory has become a critical piece of PET manufacturing and Nuclear Pharmacy.
As a nuclear pharmacist, I have been searching for the way I can better contribute to the progress of this field with an ultimate goal of proving safe and effective healthcare to the patients. In order to do so, strengthening my expertise is essential. In this thesis, I would like to capture and narrate my professional growth, by focusing on three projects, 1) Assisting in translational work for a radiolabeled monoclonal antibody, 2) Performing Germanium analysis, and 3) Establishing an environmental monitoring program at my work place.
First Committee Member (Chair)
Jeffrey P. Norenberg, PharmD, PhD,
Second Committee Member
Kristina M. Wittstrom, PhD
Level of Degree
Third Committee Member
Stephen M. Moerlein, PhD
College of Pharmacy
PET Nuclear Pharmacist, Clinical Translation, radiolabeled monoclonal antibody, Germanium analysis, environmental monitoring program
Oyama, Reiko. "Role of Nuclear Pharmacist in Clinical Translation of Positron Emission Tomography (PET) Radiopharmaceuticals and Environmental Monitoring of Facility." (2017). http://digitalrepository.unm.edu/phrm_etds/15